A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Key facts
- Where
- Alken, Gent, and Liège, BelgiumSee the 3 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07533019, who can take part
Where in Belgium
- AnimaAlken, BelgiumTaking people
- Universitair Ziekenhuis GentGent, BelgiumTaking people
- Centre Hospitalier Universitaire de LiègeLiège, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07533019EU 2025-524726-18-00
- Record updated
- 4 November 2026
- Original description
The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in participants with non-segmental vitiligo (NSV) when compared with placebo. The study drug will be administered intravenously (IV) (into a vein in the arm).Read full original descriptionShow less
A Phase 2, Randomized, 24-Week, Multicenter, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants With Non-Segmental Vitiligo
The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in participants with non-segmental vitiligo (NSV) when compared with placebo. The study drug will be administered intravenously (IV) (into a vein in the arm).
Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.
The study will last approximately 48 weeks, including screening.
Inclusion: Eligible participants must have the following at both screening and baseline:; A clinical diagnosis of non-segmented vitiligo (NSV) for at least 3 months; Body surface area (BSA) involvement of 4% to 60%, inclusive, excluding involvement at palms of the hands, soles of the feet, or dorsal aspect of the feet; BSA involvement of ≥0.5% on the face; F-VASI ≥0.5 and T-VASI ≥3, and; Either active or stable disease at both screening and baseline.
Exclusion: Have a superficial skin infection within 2 weeks before baseline. Participants may be rescreened after the infection is resolved; Have a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse within 1 year prior to screening; Any previous JAK inhibitor therapy, systemic or topical (for example, ruxolitinib, tofacitinib, baricitinib, upadacitinib, filgotinib, lestaurtinib, pacritinib) will NOT be allowed. Participant MUST be JAK inhibitor therapy-naïve; Currently have active forms of other disorders of pigmentation; Currently have active forms of inflammatory skin disease(s) or evidence of skin conditions that would interfere with evaluation of vitiligo or response to treatment; Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute an unacceptable risk when taking the study intervention or interfere with the interpretation of data; Participants who have other types of vitiligo that are not considered active or stable vitiligo.